
Marc Machaalani
@marcmachaalani
Postdoctoral Research Fellow @DanaFarber | MD '23 @LebaneseUni | Classical Pianist
ID: 1917419509
29-09-2013 15:20:41
1,1K Tweet
679 Followers
676 Following


Our kidney cancer research team Dana-Farber Lank Center for Genitourinary Oncology meeting for the 1st time #legend Robert Motzer MD at #ASCO25 after the oral session ! ASCO Memorial Sloan Kettering Cancer Center


KIM-1 is leading the biomarker strategies in #KidneyCancer ! Our very own brilliant research fellow Marc Machaalani from Dana-Farber Lank Center for Genitourinary Oncology is presenting the molecular analyses results of KIM-1! #ASCO25 Happy to be a part of this great work! Toni Choueiri, MD ASCO Renee Maria Saliby



Congratulations Marc Machaalani on an awesome poster on Kim-1 in JAVELIN renal 101 Toni Choueiri, MD ASCO #ASCO25 Renee Maria Saliby Wenxin (Vincent) Xu Eddy Saad Emre Yekedüz



Immune Checkpoint Inhibitors for Patients With Autoimmune Neurologic Disorders. Fantastic realworld collaboration on a clinically relevant Q, JAMA Network Open jamanetwork.com/journals/jaman…


My alma mater Lebanese University recognizing my mentor Toni Choueiri, MD with an honorary doctorate! Congratulations on a fitting and well-deserved distinction!


🚨Proud to share our publication in JCO Oncology Practice 🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! Toni Choueiri, MD Nazli Dizman Ziad Bakouny, MD, MSc IMG Oncologists gilberto lopes


Low KIM-1 Levels Are Associated With Improved Clinical Outcomes in Advanced RCC #RCC Marc Machaalani, MD Dana-Farber News onclive.com/view/low-kim-1…

Enjoyed working with Clara Steiner on this review of KIM-1 as a biomarker in RCC. Given the compelling retrospective data, prospective validation is the clear next step. Wenxin (Vincent) Xu Eur Urol Focus

#KCRS25 Oral Abstract: Marc Machaalani, MD Dana-Farber highlights KIM-1 as a potential blood biomarker to predict RCC treatment response and prognosis. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures


Exciting talk by David Braun at #KCRS2025 on not only the feasibility of personalized neoantigen vaccines in #kidneycancer , but also preclinical evidence of T cell response & preliminary promising clinical activity 💉🧬 KidneyCAN UroToday.com OncoAlert


Microbiome expert Carolina Alves Costa Silva, MD, PhD elegantly presentsthe data on MAdCAM-1 in association with outcomes to IO-based therapies Circulating MadCAM-1 is a promising baseline and dynamic biomarker I love our 💩team! Marc Machaalani, MD #KCRS25 OncoAlert


Takeaways from Wenxin (Vincent) Xu 's majestic talk on biomarkers: - Several biomarkers have been studied in RCC - Current biomarkers in RCC do not correspond to patient's goals - The future is in integrative biomarkers - Let's get back to work to answer all the different questions


🌟Happening now at #KCRS25👉 Marc Machaalani, MD presenting an integrative clinical, genomic, transcriptomic and immunopathologic analysis of circulating KIM-1 in metastatic RCC #kidneycancer👇 KidneyCAN OncoAlert UroToday.com


Rocking the stage Marc Machaalani, MD with his work on KIM-1 levels in JAVELINE 101 trial: 1. Patients with higher levels of KIM1 at baseline worse OS, PFS. 2. KIM 1 levels associated with BAP1 and proliferative signature. 3. KIM1 + IMDC + change in KIM1 achieved an AUC of 0.76



A sharp and insightful talk at #KCRS25 about KIM-1 in JAVELIN Renal 101 by my dear colleague Marc Machaalani, MD — another key step in the evolving story of KIM-1 in RCC with more to come!! Wenxin (Vincent) Xu Toni Choueiri, MD
